Tuesday, 20 August 2019

Celgene, Evotec team up on cancer treatments

22 May 2018 | News

Under the terms of collaboration, Evotec will receive $65M upfront.

Singapore- Celgene and German biotech Evotec AG have inked a long-term strategic drug discovery and development partnership to identify new cancer therapies, 18 months after the two companies allied on neurodegeneration work.

Under the terms of collaboration, Evotec will receive $65M upfront, and may be eligible to receive significant milestone payments as well as tiered royalties on each licensed programme. Celgene receives exclusive opt-in rights to license worldwide rights to all programmes developed within this collaboration.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Will APAC lead the way for innovation in the field of precision medicine?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls